However, when we dichotomized the HNSCC cohort based on the median expression levels of BTN3A1/BTN3A2/BTN3A3/BTN2A1, we found that although there was no statistical significance between the high and low groups, the patients with higher expression levels of the BTN family proteins showed better overall survival than patients whose expression levels were lower than the median expression levels (P > 0.05, Supplementary Figure 3B). The gene discussed is BTN3A2; the disease is head and neck squamous cell carcinoma.